Thermo Fisher Scientific (NYSE:TMO) Hits New 12-Month High – Here’s Why

Thermo Fisher Scientific Inc. (NYSE:TMO)’s stock price reached a new 52-week high on Wednesday. The company traded as high as $727.56 and last traded at $723.2760, with a volume of 128,674 shares trading hands. The stock had previously closed at $718.20.

Thermo Fisher Scientific News Summary

These are some of the TMO news items that stood out recently:

• Positive Sentiment: A report discusses Thermo Fisher’s $5 billion buyback, putting its cash generation and capital returns in focus. Repurchases can support per-share results and signal confidence, though the article also questions whether cash flows justify expectations after the stock’s strong multiyear return. Is Thermo Fisher Scientific Reasonable After Its $5 Billion Buyback?
• Neutral Sentiment: Industry reports project growth in markets where Thermo Fisher competes, including single-use bioprocessing, cell lysis and cell-culture coatings. These forecasts suggest favorable longer-term demand, but are broad market estimates—not evidence of new orders or a change in the company’s outlook. Single-Use Bioprocessing Market Report
• Neutral Sentiment: Other coverage notes TMO’s strong recent share performance and considers whether its cash generation can sustain investor expectations. That highlights potential valuation sensitivity, but provides no new earnings warning or negative company announcement. What Happened To People Who Bought Thermo Fisher Stock At A High?

Analysts Set New Price Targets

A number of equities research analysts have issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Thermo Fisher Scientific from $690.00 to $760.00 and gave the stock an “overweight” rating in a report on Wednesday, October 14th. Rothschild & Co Redburn upped their price objective on shares of Thermo Fisher Scientific from $725.00 to $750.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Deutsche Bank increased their price objective on Thermo Fisher Scientific from $720.00 to $750.00 and gave the stock a “buy” rating in a report on Thursday, October 22nd. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $650.00 to $730.00 and gave the company an “overweight” rating in a research note on Monday, October 12th. Finally, Scotiabank initiated coverage on Thermo Fisher Scientific in a research note on Wednesday, September 9th. They issued an “outperform” rating on the stock. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $683.64.

Thermo Fisher Scientific Stock Down 2.5%

The company’s 50 day simple moving average is $669.20 and its 200-day simple moving average is $556.44. The company has a current ratio of 1.81, a quick ratio of 1.41 and a debt-to-equity ratio of 0.71. The firm has a market cap of $259.20 billion, a P/E ratio of 36.90, a PEG ratio of 2.92 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The firm had revenue of $12.14 billion during the quarter, compared to analyst estimates of $11.95 billion. During the same period in the previous year, the business posted $5.79 earnings per share. The business’s revenue for the quarter was up 9.1% on a year-over-year basis. Research analysts forecast that Thermo Fisher Scientific Inc. will post 25.27 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, January 15th. Shareholders of record on Tuesday, December 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, December 15th. Thermo Fisher Scientific’s payout ratio is 9.92%.

Insiders Place Their Bets

In related news, VP Lisa P. Britt sold 2,831 shares of the business’s stock in a transaction that occurred on Wednesday, October 28th. The shares were sold at an average price of $706.45, for a total transaction of $1,999,959.95. Following the completion of the sale, the vice president directly owned 11,560 shares in the company, valued at approximately $8,166,562. The trade was a 19.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 275 shares of the company’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at $77,707,171.25. This trade represents a 0.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 24,546 shares of company stock valued at $15,479,192. Company insiders own 0.33% of the company’s stock.

Institutional Investors Weigh In On Thermo Fisher Scientific

Institutional investors have recently bought and sold shares of the business. Disciplined Investors L.L.C. purchased a new position in shares of Thermo Fisher Scientific during the third quarter valued at $206,000. Bouchey Financial Group Ltd. lifted its position in Thermo Fisher Scientific by 22.0% during the third quarter. Bouchey Financial Group Ltd. now owns 499 shares of the medical research company’s stock valued at $337,000 after acquiring an additional 90 shares during the last quarter. Gabelli Funds LLC boosted its position in shares of Thermo Fisher Scientific by 1.4% in the 3rd quarter. Gabelli Funds LLC now owns 16,310 shares of the medical research company’s stock worth $11,010,000 after purchasing an additional 220 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co boosted its holdings in Thermo Fisher Scientific by 3.4% in the third quarter. Ilmarinen Mutual Pension Insurance Co now owns 57,200 shares of the medical research company’s stock worth $38,613,000 after acquiring an additional 1,900 shares in the last quarter. Finally, Fort Sheridan Advisors LLC grew its position in Thermo Fisher Scientific by 1.7% during the 3rd quarter. Fort Sheridan Advisors LLC now owns 3,431 shares of the medical research company’s stock worth $2,316,000 after purchasing an additional 58 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific develops and supplies products and services used in scientific research, clinical diagnostics, and pharmaceutical and biotechnology manufacturing. Its offerings include laboratory instruments, reagents and consumables, analytical equipment, diagnostic tests, and services that support drug development and clinical research. The company operates through businesses focused on life sciences, analytical instruments, specialty diagnostics, and laboratory products and biopharma services.